Suicide gene therapy of rhabdomyosarcoma

Area of Science:

• Oncology
• Gene Therapy
• Cancer Research

Background:

• Rhabdomyosarcoma is a prevalent soft tissue sarcoma in pediatric and young adult populations.
• Conventional treatments often prove insufficient, especially upon cancer recurrence, highlighting the need for innovative therapies.
• Novel therapeutic strategies are crucial for improving long-term survival rates in rhabdomyosarcoma patients.

Purpose of the Study:

• To evaluate the efficacy of suicide gene therapy for rhabdomyosarcoma using the herpes simplex thymidine kinase (HSV-TK) and ganciclovir (GCV) system.
• To assess the gene therapy's effectiveness in eradicating rhabdomyosarcoma cells both in vitro and in vivo.
• To investigate the role of gap junctional intercellular communication in the bystander effect of this suicide gene therapy.

Main Methods:

• Lentiviral vectors were employed for efficient transduction of the HSV-TK gene into the Rh30 rhabdomyosarcoma cell line.
• Modified and unmodified cells were treated with ganciclovir (GCV) to assess cancer cell eradication.
• In vivo studies involved systemic administration of GCV to evaluate tumor remission in a rhabdomyosarcoma model.

Main Results:

• Transduced rhabdomyosarcoma cells showed high susceptibility to ganciclovir, leading to significant cancer cell death in vitro.
• A potent bystander effect was observed, mediated by gap junctional intercellular communication, eliminating unmodified cells even when HSV-TK expressing cells were scarce (20%).
• Complete tumor remission was achieved in vivo within 14 days of systemic GCV administration, demonstrating the therapy's potent anti-cancer activity.

Conclusions:

• HSV-TK/GCV suicide gene therapy is a highly effective strategy against rhabdomyosarcoma.
• The bystander effect, enhanced by gap junction communication, significantly contributes to the therapy's efficacy.
• This approach shows considerable promise for future clinical applications in rhabdomyosarcoma treatment.